Comparative Effects of 2 Diets in Veterans With the Metabolic Syndrome (MUFA PUFA)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to examine the effects of 2 commonly used diets, a Mediterranean monounsaturated fatty acid enriched (MUFA) or AHA polyunsaturated (PUFA) enriched diet combined with the VA Managing Overweight/Obesity for Veterans Everywhere (MOVE!) program so as to determine which one is superior in reducing cardiometabolic risk factors associated with Metabolic Syndrome. The risk factors considered include lipids and lipoproteins, inflammatory markers such as CRP and adiponectin, endothelium-dependent flow-mediated vasodilatation (FMD) and the postprandial lipid responses to a meal.
Cardiometabolic risk factors will be determined by measuring several cardiovascular risk associated parameters including:
Biochemical measurements of lipids and inflammatory markers, body composition and VO2max (Specific Objective 1, Descriptive).
Postprandial response to a meal challenge and endothelial vasoreactivity (FMD) assessed by BART (Specific Objective 2, Physiological).
Determination of the effects on postheparin lipases and transfer protein activity, visceral adipose tissue (VAT) and homeostasis model assessment-estimated insulin resistance (HOMA-IR) (Specific Objective 3, Mechanistic)
| Condition | Intervention |
|---|---|
|
Metabolic Syndrome |
Dietary Supplement: MUFA MOVE! (Monounsaturated fatty enriched diet) Dietary Supplement: PUFA MOVE! (Polyunsaturated fatty acid enriched diet) |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Comparative Effects of Two Popular Diets in Veterans With the Metabolic Syndrome |
- Metabolic (lipid, glucose, insulin resistance), body composition (assessed via dual energy absorptiometry DXA and CT-scan), and CV fitness (assessed as maximal aerobic capacity, VO2max) abnormalities in Veterans with MetS. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
- Endothelium-dependent FMD assessed by the brachial artery reactivity test (BART) at rest and after postprandial meal challenge (lipid and glucose) responses. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
- (1) lipolytic enzymes and transfer proteins that mediate the lipid changes, (2) insulin resistance for glucose, (3) visceral adipose tissue area for lipids and glucose and (4) BART for vascular endothelial function and atherosclerosis. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 70 |
| Study Start Date: | February 2010 |
| Estimated Study Completion Date: | April 2014 |
| Primary Completion Date: | April 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Placebo Comparator: Arm 1
Assignment to monounsaturated enriched diet with the MUFA MOVE! program
|
Dietary Supplement: MUFA MOVE! (Monounsaturated fatty enriched diet)
MUFA diet and exercise program
|
|
Active Comparator: Arm 2
PUFA diet MOVE! exercise
|
Dietary Supplement: PUFA MOVE! (Polyunsaturated fatty acid enriched diet)
PUFA diet and exercise
|
Detailed Description:
The Metabolic Syndrome (MetS) is a common problem among Veterans and is associated with a greater likelihood of cardiovascular disease (CVD). The Mediterranean diet is the only popular diet that has been shown to reduce CVD event rates but the extent to which monounsaturated fatty acid (MUFA) or polyunsaturated fatty acid (PUFA) enrichment results in improvement in parameters of MetS is unresolved. Similarly, while low intensity exercise improves the CVD risk factor profile, there have been no comparative investigations comparing MUFA and PUFA enriched diets and exercise in patients with MetS that have extended beyond 1 year. Recently, the VA established the MOVE! program, a national weight management program designed to help Veterans lose weight. Using the VA promoted program, we will perform a systematic evaluation of the effects of dietary fat composition [comparison between MUFA-enriched and PUFA enriched diet] with MOVE!. We hypothesize that a MUFA-enriched diet consisting of antioxidant, lipid reducing and insulin sensitizing properties will be superior to the less palatable PUFA-enriched diet on improving cardiometabolic parameters associated with MetS. Specifically, the MUFA MOVE! program is expected to lead to greater improvements than the PUFA MOVE! program in body composition and aerobic fitness (Specific Aim 1), endothelial dependent flow mediated vasodilatation and the postprandial lipid response to a meal load (Specific Aim 2) and the mechanisms (lipolytic and lipid transfer protein activity, homeostasis model assessment-estimated insulin resistance) responsible for these effects (Specific Aim 3). Collectively, these studies will advance our understanding of mechanisms underlying the differential effects of MUFA and PUFA-enriched dietary regimens on cardiometabolic health and when combined with the MOVE! program, will provide new and useful information to Veterans (and the general public) interested in optimizing their diets for CVD disease prevention and improved vascular health.
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Presence of 3 or more of the following):
- Waist circumference >102 cm in men or >88 cm women
- Treated Hypertension or Untreated Blood pressure >130/85 and < 160/100 mm Hg
- Treated Hyperglycemia or Untreated Fasting blood glucose (FBG) >100 mg/dL (based on 2006 guidelines)
- Treated Hyperlipidemia or Untreated Triglycerides > 150 mg/dL
- HDL-C < 40 mg/dL men < 50 mg/dL women
Exclusion Criteria:
- Decompensated heart failure (NYHA Class IV);
- Severe Pulmonary disease (Unable to walk on a treadmill at 2.5 mph or greater);
- Chronic renal insufficiency (Cr > 2.5 mg/dL)
- Treated diabetes mellitus with FBG > 180 mg/dL or HbA1C >9g %
- Hematologic or malignant disorders
- Treated SBP >160 mmHg and/or DBP > 95 mmHg ;
- Treated TG > 250 mg/dL
- Use of systemic vasodilators (e.g., nitrates)
- Morbid Obesity (BMI > 50 kg/m2)
- Endocrine (thyroid) or metabolic disorders (unless treated and under control)
- Alcohol consumption greater than (2) 4-ounce glasses of table wine, (2) 12-oz bottles of beer or 2 shots of spirits in men or women
- Active IV drug abuse within the past 6 months
Contacts and Locations| United States, Maryland | |
| VA Maryland Health Care System, Baltimore | |
| Baltimore, Maryland, United States, 21201 | |
| Principal Investigator: | Michael Miller, MD | VA Maryland Health Care System, Baltimore |
More Information
No publications provided
| Responsible Party: | Department of Veterans Affairs |
| ClinicalTrials.gov Identifier: | NCT00852475 History of Changes |
| Other Study ID Numbers: | CARA-006-08F, HP-00040456 |
| Study First Received: | February 26, 2009 |
| Last Updated: | June 12, 2013 |
| Health Authority: | United States: Federal Government |
Keywords provided by Department of Veterans Affairs:
|
MUFA PUFA MOVE! program |
Additional relevant MeSH terms:
|
Metabolic Syndrome X Insulin Resistance Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases |
ClinicalTrials.gov processed this record on June 18, 2013